Nurix Extends Collaboration with Gilead

 Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates

Nurix will receive a $15.0 million extension fee, and will remain eligible for up to an additional $73.5 million in potential preclinical research milestones and licensing fees, and up to $1.7 billion in potential future development, regulatory, and sales milestones as well as royalties on future products

Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States

https://www.globenewswire.com/news-release/2024/04/02/2855797/0/en/Nurix-Therapeutics-Announces-Extension-of-Strategic-Collaboration-with-Gilead-Sciences.html